MediWound’s (MDWD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of MediWound (NASDAQ:MDWD) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $25.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MediWound’s FY2029 earnings at $2.45 EPS.

Separately, Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 target price on the stock.

MediWound Trading Down 4.6 %

MDWD stock opened at $16.27 on Thursday. The company’s 50 day moving average is $18.17 and its two-hundred day moving average is $17.59. The stock has a market cap of $175.60 million, a P/E ratio of -5.61 and a beta of 0.82. MediWound has a twelve month low of $12.78 and a twelve month high of $24.00.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23. The business had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the company posted ($0.19) EPS. On average, equities research analysts predict that MediWound will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

A number of hedge funds and other institutional investors have recently bought and sold shares of MDWD. Investor AB purchased a new position in MediWound in the 3rd quarter valued at $15,750,000. Yelin Lapidot Holdings Management Ltd. grew its position in MediWound by 13.4% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock valued at $15,154,000 after buying an additional 100,618 shares during the last quarter. Northern Trust Corp grew its position in MediWound by 94.6% in the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock valued at $2,577,000 after buying an additional 70,367 shares during the last quarter. State Street Corp grew its position in MediWound by 219.6% in the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 45,529 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in MediWound by 30.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after buying an additional 35,012 shares during the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.